 |
|
|
| |
Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in routine clinical practice
|
| |
| |
Reported by Jules Levin
17th EACS Basel 2019 Nov 6-9
Postel Nils1, HeuchelThomas2, MalfertheinerPeter3, Brust Jurgen4, Scholten Stefan5, Stephan Christoph6, Bohr Ulrich7, Hillenbrand Heribert8, Lutz Thomas9, GlaunsingerTobias10, WestermayerBernd11, Luftenegger Daniel12, Walli Ravi-K12 on behalf of the TRIUMPH study team
1prinzmed, Munich; 2Medcenter, Chemnitz; 3Universitatsklinikum Magdeburg, Magdeburg; 4Mannheimer OnkologiePraxis, Mannheim; 5Praxis Hohenstaufenring, Cologne; 6Universitatsklinikum-HIVcenter, Frankfurt am Main ; 7Praxiszentrum Kaiserdamm, Berlin; 8Praxis City Ost, Berlin; 9Infektiologikum, Frankfurt; 10Praxis Prenzlauer Berg, Berlin; 11GlaxoSmithKline, Munich; 12ViiV Healthcare, Munich
|
| |
|
|
|
|
|
